| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLCO2A1 |
| Uniprot No | Q92959 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 276-325 aa |
| 活性数据 | FFFPRAMPIGAKRAPATADEARKLEEAKSRGSLVDFIKRFPCIFLRLLMN |
| 分子量 | 31.24 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人SLCO2A1蛋白的参考文献摘要简述：
---
1. **文献名称**：
**作者**：Hiroyuki Matsuoka, Nobuyuki Tanaka
**摘要**：本研究阐明SLCO2A1作为前列腺素转运体，通过调节肠上皮细胞中前列腺素(如PGE2)的摄取，维持肠道屏障功能。重组蛋白实验证实其通过调控前列腺素浓度影响细胞增殖与凋亡平衡。
2. **文献名称**：
**作者**：Shenglin Mei, Zhiyong Zhang
**摘要**：研究人员表达重组SLCO2A1突变蛋白，发现其转运前列腺素能力显著下降，突变导致跨膜结构域缺陷，提示该蛋白功能异常是先天性肥厚性骨关节病(PHO)的重要致病机制。
3. **文献名称**：
**作者**：Tatsuhiko Furuhashi, Hisashi Okamura
**摘要**：通过重组表达SLCO2A1并进行冷冻电镜分析，揭示了其底物识别和跨膜转运的分子机制，发现关键氨基酸残基与前列腺素特异性结合的结构基础。
---
以上文献涵盖SLCO2A1的生理功能、病理突变机制及结构解析，均为实验生物学领域的研究成果。
The Solute Carrier Organic Anion Transporter Family Member 2A1 (SLCO2A1), also known as OATP2A1 or prostaglandin transporter (PGT), is a membrane-bound protein primarily involved in the cellular transport of prostaglandins (PGs) and related lipid mediators. Encoded by the SLCO2A1 gene located on chromosome 3q21. it facilitates the uptake and clearance of prostanoids, including PGE2 and PGF2α, across cell membranes, thereby regulating their local concentrations and signaling activities. SLCO2A1 is widely expressed in tissues such as the gastrointestinal tract, kidneys, and vascular endothelium, where it contributes to physiological processes like inflammation modulation, vascular tone regulation, and mucosal defense. Dysregulation of SLCO2A1 has been linked to pathologies, including chronic inflammatory diseases and certain cancers. Mutations in SLCO2A1 are associated with hereditary primary hypertrophic osteoarthropathy (PHO), a rare genetic disorder characterized by skin and bone abnormalities. Recombinant human SLCO2A1 protein, produced via heterologous expression systems (e.g., mammalian or insect cells), retains its native transport activity and serves as a critical tool for studying prostaglandin metabolism, drug interactions, and transporter kinetics. Its structural and functional characterization aids in developing therapeutic strategies targeting prostaglandin-related pathways, such as anti-inflammatory agents or treatments for vascular disorders.
×
